Blood Vessel Models for High-Throughput Therapy Screening
Learn More
Enhanced preclinical testing of blood vessel interactions improves therapy targeting
Research Project
Prototype developed
76 •
Challenge
Therapies must cross the blood vessel wall to reach target sites, yet only ~ 2 % of nanomedicines succeed.
Conventional lab models poorly mimic human vessels, limiting formulation selection and optimisation. This has resulted in the poor translation of nanomedicines optimised in conventional lab and animal models to clinical use.
Solution
The team’ s high-throughput platform precisely replicates the human blood vessel wall in healthy or diseased states. It enables organisations to optimise therapeutics and nanomedicines in highthroughput preclinical laboratory environments to increase the pipeline of therapies for the clinical use.
Target customers / end-users
• biotech and pharmaceutical companies
• medical research organisations
• contract research organisations( CROs).
Progress
• completed pilot with Synedgen Inc. demonstrating feasibility in selecting candidates for further preclinical testing
• key prototype tested successfully in polymer and nanoparticle screening
• dissemination in multiple peerreviewed articles.
TRL 3
Multidisciplinary team
Healthy Living
This team’ s high-throughput platform precisely replicates the blood vessel wall in healthy and diseased states, such as cardiovascular disease, diabetes and cancer, enabling efficient screening of therapeutic formulations. This technology enhances preclinical development and has already been adopted by a US biotech company advancing polymer-based solutions across diverse healthcare applications.